268 research outputs found
‘Misschien’ – Een eenvoudig bijwoord als theologische blikopener
Het woord 'misschien', zeker als God zelf het in de mond neemt, heeft merkwaardige gevolgen voor het denken over God en de geschiedenis. Dit artikel doordenkt die gevolgen, en pleit op grond daarvan voor een systematische theologie die minder systematisch dichtgetimmerd is, en meer openstaat voor het contingente en verrassende, dat de bijbelse narratieve traditie laat zien
"The leading role of pathology in assessing the somatic molecular alterations of cancer:Position Paper of the European Society of Pathology": letter to the Editor
Contains fulltext :
232005.pdf (Publisher’s version ) (Open Access
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase
Transglutaminases (TGases) are calcium-dependent enzymes catalysing the
post-translational cross-linking of proteins. In the prostate at least two
TGases are present, the ubiquitously expressed tissue-type TGase (TGC),
and a prostate-restricted TGase (TGP). This paper deals with the molecular
cloning and characterization of the cDNA encoding the human prostate TGase
(hTGP). For this purpose we have screened a human prostate cDNA library
with a probe from the active-site region of TGC. The largest isolated cDNA
contained an open reading frame encoding a protein of 684 amino acids with
a predicted molecular mass of 77 kDa as confirmed by in vitro
transcription-translation and subsequent SDS/PAGE. The hTGP gene was
tissue-specifically expressed in the prostate, yielding an mRNA of approx.
3.5 kb. Furthermore, a 3-fold androgen-induced upregulation of hTGP mRNA
expression has been demonstrated in the recently developed human prostate
cancer cell line, PC346C. Other well established human prostate cancer
cell lines, LNCaP and PC-3, showed no detectable hTGP mRNA expression on a
Northern bolt. The gene coding for prostate TGase was assigned to
chromosome 3
Molecular alterations and potential actionable mutations in peritoneal mesothelioma:a scoping review of high-throughput sequencing studies
Background: Peritoneal mesothelioma (PeM) is a rare malignancy with a poor prognosis. Currently there is a lack of effective systemic therapies. Due to the rarity of PeM, it is challenging to study new treatment options. Off-label use of targeted drugs could be an effective approach. This scoping review aims to explore the genomic landscape of PeM to identify potential therapeutic targets. Materials and methods: A systematic literature search of Embase, Medline, Web of Science, the Cochrane Library, and Google Scholar was carried out up to 1 November 2022. Studies that reported on molecular alterations in PeM detected by high-throughput sequencing techniques were included. Genes that were altered in ≥1% of PeMs were selected for the identification of potential targeted therapies. Results: Thirteen articles were included, comprising 824 PeM patients. In total, 142 genes were altered in ≥1% of patients, of which 7 genes were altered in ≥10%. BAP1 was the most commonly altered gene (50%). Other commonly altered genes were NF2 (25%), CDKN2A (23%), CDKN2B (17%), PBRM1 (15%), TP53 (14%), and SETD2 (13%). In total, 17% of PeM patients were carriers of a germline mutation, mainly in BAP1 (7%). Conclusions: This scoping review provides an overview of the mutational landscape of PeM. Germline mutations might be a larger contributor to the incidence of PeM than previously thought. Currently available targeted therapy options are limited, but several targeted agents [such as poly (ADP-ribose) polymerase (PARP), enhancer of zeste homolog 2 (EZH2), and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors] were identified that might provide new targeted therapy options in the future.</p
- …